Nonglycemic Effects of GLP-1 Agonists

From a Starling to Lizards to People

Research output: Contribution to journalReview article

Abstract

With the approval of exenatide in 2005, physicians had a new class of hypoglycemic agents available for the treatment of type 2 diabetes-the glucagon-like peptide-1 receptor agonists (or GLP-1 receptor agonists). As of this writing, there are seven drugs in this class available in the United States. In addition to demonstrating either cardiovascular risk neutrality or overt benefit, as now mandated by the United States Food and Drug Administration (FDA), many of these drugs have other, unexpected actions. It is our goal to outline these actions, some beneficial, some not. We have reviewed English-language articles in this area, not for an exhaustive study, but rather a broad search to define current understanding and perhaps generate further investigation.

Original languageEnglish (US)
Pages (from-to)303-313
Number of pages11
JournalMetabolic Syndrome and Related Disorders
Volume17
Issue number6
DOIs
StatePublished - Jul 1 2019

Fingerprint

Starlings
Glucagon-Like Peptide 1
Lizards
United States Food and Drug Administration
Hypoglycemic Agents
Pharmaceutical Preparations
Type 2 Diabetes Mellitus
Language
Physicians
Glucagon-Like Peptide-1 Receptor
Therapeutics
exenatide

Keywords

  • appetite
  • blood pressure
  • GLP-1 agonists
  • secondary effects
  • type 2 diabetes

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism

Cite this

Nonglycemic Effects of GLP-1 Agonists : From a Starling to Lizards to People. / Sood, Ajay; Swislocki, Arthur L.

In: Metabolic Syndrome and Related Disorders, Vol. 17, No. 6, 01.07.2019, p. 303-313.

Research output: Contribution to journalReview article

@article{337dfe96da054cd984b04deb1031cef6,
title = "Nonglycemic Effects of GLP-1 Agonists: From a Starling to Lizards to People",
abstract = "With the approval of exenatide in 2005, physicians had a new class of hypoglycemic agents available for the treatment of type 2 diabetes-the glucagon-like peptide-1 receptor agonists (or GLP-1 receptor agonists). As of this writing, there are seven drugs in this class available in the United States. In addition to demonstrating either cardiovascular risk neutrality or overt benefit, as now mandated by the United States Food and Drug Administration (FDA), many of these drugs have other, unexpected actions. It is our goal to outline these actions, some beneficial, some not. We have reviewed English-language articles in this area, not for an exhaustive study, but rather a broad search to define current understanding and perhaps generate further investigation.",
keywords = "appetite, blood pressure, GLP-1 agonists, secondary effects, type 2 diabetes",
author = "Ajay Sood and Swislocki, {Arthur L}",
year = "2019",
month = "7",
day = "1",
doi = "10.1089/met.2018.0134",
language = "English (US)",
volume = "17",
pages = "303--313",
journal = "Metabolic Syndrome and Related Disorders",
issn = "1540-4196",
publisher = "Mary Ann Liebert Inc.",
number = "6",

}

TY - JOUR

T1 - Nonglycemic Effects of GLP-1 Agonists

T2 - From a Starling to Lizards to People

AU - Sood, Ajay

AU - Swislocki, Arthur L

PY - 2019/7/1

Y1 - 2019/7/1

N2 - With the approval of exenatide in 2005, physicians had a new class of hypoglycemic agents available for the treatment of type 2 diabetes-the glucagon-like peptide-1 receptor agonists (or GLP-1 receptor agonists). As of this writing, there are seven drugs in this class available in the United States. In addition to demonstrating either cardiovascular risk neutrality or overt benefit, as now mandated by the United States Food and Drug Administration (FDA), many of these drugs have other, unexpected actions. It is our goal to outline these actions, some beneficial, some not. We have reviewed English-language articles in this area, not for an exhaustive study, but rather a broad search to define current understanding and perhaps generate further investigation.

AB - With the approval of exenatide in 2005, physicians had a new class of hypoglycemic agents available for the treatment of type 2 diabetes-the glucagon-like peptide-1 receptor agonists (or GLP-1 receptor agonists). As of this writing, there are seven drugs in this class available in the United States. In addition to demonstrating either cardiovascular risk neutrality or overt benefit, as now mandated by the United States Food and Drug Administration (FDA), many of these drugs have other, unexpected actions. It is our goal to outline these actions, some beneficial, some not. We have reviewed English-language articles in this area, not for an exhaustive study, but rather a broad search to define current understanding and perhaps generate further investigation.

KW - appetite

KW - blood pressure

KW - GLP-1 agonists

KW - secondary effects

KW - type 2 diabetes

UR - http://www.scopus.com/inward/record.url?scp=85070458368&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85070458368&partnerID=8YFLogxK

U2 - 10.1089/met.2018.0134

DO - 10.1089/met.2018.0134

M3 - Review article

VL - 17

SP - 303

EP - 313

JO - Metabolic Syndrome and Related Disorders

JF - Metabolic Syndrome and Related Disorders

SN - 1540-4196

IS - 6

ER -